Physician profile
Jerrold C Bustos
NPI 1942251384
$3,396.27
in general payments reported to CMS, 2019-2025
32 companies · $19.48 in 2025
The $19.48 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $731 · 2021: $590 · 2022: $659 · 2023: $735 · 2025: $19.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $649.42 | 2019-2023 | Belbuca |
| Boston Scientific Corporation | $537.35 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Abbott Laboratories | $436.40 | 2019-2023 | Proclaim |
| Biodelivery Sciences International, INC. | $257.03 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $162.58 | 2022-2023 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.15 | 2022 | |
| Sentynl Therapeutics, INC. | $135.24 | 2019-2020 | |
| Forte Bio-Pharma LLC | $117.07 | 2020-2023 | Prolate, Nalocet |
| Medtronic, INC. | $113.02 | 2023 | Intellis Adaptivestim |
| Almatica Pharma LLC | $105.23 | 2021-2023 | Gralise |
| Grt US Holding, INC. | $100.81 | 2020-2022 | |
| Zyla Life Sciences, INC. | $83.26 | 2019-2020 | |
| Redhill Biopharma INC. | $80.57 | 2020-2021 | |
| Nevro Corp. | $56.87 | 2019-2020 | |
| Fidia Pharma USA INC. | $49.64 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46.74 | 2019 | |
| Abbvie INC. | $34.91 | 2022 | |
| Ibsa Pharma INC. | $34.06 | 2023 | Tirosint, Licart |
| Si-Bone, INC. | $31.42 | 2019-2020 | |
| Avanos Medical | $24.30 | 2019 | |
| Bioventus LLC | $21.83 | 2021 | |
| Daiichi Sankyo INC. | $21.68 | 2019 | |
| Lilly USA, LLC | $21.15 | 2021 | |
| Virtus Pharmaceuticals LLC | $20.35 | 2023 | Levorphanol Tartrate |
| Alnylam Pharmaceuticals INC. | $17.39 | 2021 | |
| Medtronic USA, INC. | $17.30 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.33 | 2021 | |
| Horizon Therapeutics Plc | $15.19 | 2022 | |
| Nalu Medical, INC. | $14.62 | 2021 | |
| Valinor Pharma, LLC | $13.93 | 2023 | Movantik |
| Kowa Pharmaceuticals America, INC. | $13.36 | 2023 | Seglentis |
| Vertos Medical, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerrold Bustos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.